Huntington Disease (Central Nervous System) - Drugs in Development, 2021

November 2021 | 423 pages | ID: H88FF8C987DAEN
Global Markets Direct

Abstracts

Huntington Disease (Central Nervous System) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Huntington Disease - Drugs In Development, 2021, provides an overview of the Huntington Disease (Central Nervous System) pipeline landscape.

Huntington's disease (HD) is an inherited disease that causes certain nerve cells in the brain to waste away. HD is a familial disease that is passed on from parent to child through a mutation in their genes. Early symptoms of HD include uncontrolled movements, clumsiness, and balance problems. Later, HD can take away the ability to walk, talk, and swallow.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Huntington Disease - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Huntington Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Huntington Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Huntington Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 9, 14, 2, 66, 30 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 21 and 6 molecules, respectively.

Huntington Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Huntington Disease (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Huntington Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Huntington Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Huntington Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Huntington Disease (Central Nervous System)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Huntington Disease (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Huntington Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Huntington Disease - Overview
Huntington Disease - Therapeutics Development
Huntington Disease - Therapeutics Assessment
Huntington Disease - Companies Involved in Therapeutics Development
Huntington Disease - Drug Profiles
Huntington Disease - Dormant Projects
Huntington Disease - Discontinued Products
Huntington Disease - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Huntington Disease, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Huntington Disease - Pipeline by Acen Regenerative Medicine Sci-Tech Co Ltd, 2021
Huntington Disease - Pipeline by Adeptio Pharmaceuticals Ltd, 2021
Huntington Disease - Pipeline by AFFiRiS AG, 2021
Huntington Disease - Pipeline by Alchemab Therapeutics Ltd, 2021
Huntington Disease - Pipeline by Alkermes Plc, 2021
Huntington Disease - Pipeline by Alnylam Pharmaceuticals Inc, 2021
Huntington Disease - Pipeline by Alsonex Pty Ltd, 2021
Huntington Disease - Pipeline by Anima Biotech Inc, 2021
Huntington Disease - Pipeline by Annexon Inc, 2021
Huntington Disease - Pipeline by Annji Pharmaceutical Co Ltd, 2021
Huntington Disease - Pipeline by Aop Orphan Pharmaceuticals AG, 2021
Huntington Disease - Pipeline by ArunA Biomedical Inc, 2021
Huntington Disease - Pipeline by Arvinas Inc, 2021
Huntington Disease - Pipeline by Asahi Kasei Pharma Corp, 2021
Huntington Disease - Pipeline by Asdera LLC, 2021
Huntington Disease - Pipeline by Asklepios BioPharmaceutical Inc, 2021
Huntington Disease - Pipeline by Atalanta Therapeutics Inc, 2021
Huntington Disease - Pipeline by Avergen Pharmaceuticals GmbH, 2021
Huntington Disease - Pipeline by Azevan Pharmaceuticals Inc, 2021
Huntington Disease - Pipeline by Berg LLC, 2021
Huntington Disease - Pipeline by Bionaut Labs Inc, 2021
Huntington Disease - Pipeline by Biorchestra Co Ltd, 2021
Huntington Disease - Pipeline by BrainStorm Cell Therapeutics Inc, 2021
Huntington Disease - Pipeline by Brainvectis SAS, 2021
Huntington Disease - Pipeline by Cellavita Pesquisa Cientifica Ltda, 2021
Huntington Disease - Pipeline by Celon Pharma SA, 2021
Huntington Disease - Pipeline by Ceptur Therapeutics Inc, 2021
Huntington Disease - Pipeline by Chaperone Pharma BV, 2021
Huntington Disease - Pipeline by Chaperone Therapeutics Inc, 2021
Huntington Disease - Pipeline by Chong Kun Dang Pharmaceutical Corp, 2021
Huntington Disease - Pipeline by Cleave Therapeutics Inc, 2021
Huntington Disease - Pipeline by Collaborative Medicinal Development LLC, 2021
Huntington Disease - Pipeline by DanPET AB, 2021
Huntington Disease - Pipeline by Dystrogen Therapeutics SA, 2021
Huntington Disease - Pipeline by Emerald Health Sciences Inc, 2021
Huntington Disease - Pipeline by Enzerna Biosciences LLC, 2021
Huntington Disease - Pipeline by Exicure Inc, 2021
Huntington Disease - Pipeline by Exopharm Ltd, 2021
Huntington Disease - Pipeline by F. Hoffmann-La Roche Ltd, 2021
Huntington Disease - Pipeline by Forest Hills Partners Hong Kong Ltd, 2021
Huntington Disease - Pipeline by Immungenetics AG, 2021
Huntington Disease - Pipeline by Incisive Genetics Inc, 2021
Huntington Disease - Pipeline by InnoMedica Holding AG, 2021
Huntington Disease - Pipeline by Janusq LLC, 2021
Huntington Disease - Pipeline by KeifeRx LLC, 2021
Huntington Disease - Pipeline by Sosei Group Corp, 2021
Huntington Disease - Pipeline by Spark Therapeutics Inc, 2021
Huntington Disease - Pipeline by Stealth BioTherapeutics Corp, 2021
Huntington Disease - Pipeline by Suven Life Sciences Ltd, 2021
Huntington Disease - Pipeline by T3D Therapeutics Inc, 2021
Huntington Disease - Pipeline by Takeda Pharmaceutical Co Ltd, 2021
Huntington Disease - Pipeline by Teitur Trophics ApS, 2021
Huntington Disease - Pipeline by Teva Pharmaceutical Industries Ltd, 2021
Huntington Disease - Pipeline by Trailhead Biosystems Inc, 2021
Huntington Disease - Pipeline by TreeFrog Therapeutics SAS, 2021
Huntington Disease - Pipeline by Triplet Therapeutics Inc, 2021
Huntington Disease - Pipeline by Ultragenyx Pharmaceutical Inc, 2021
Huntington Disease - Pipeline by UniQure NV, 2021
Huntington Disease - Pipeline by Vaccinex Inc, 2021
Huntington Disease - Pipeline by Vanqua Bio Inc, 2021
Huntington Disease - Pipeline by Vico Therapeutics BV, 2021
Huntington Disease - Pipeline by Vitality Biopharma Inc, 2021
Huntington Disease - Pipeline by Vivoryon Therapeutics NV, 2021
Huntington Disease - Pipeline by Voyager Therapeutics Inc, 2021
Huntington Disease - Pipeline by Vybion Inc, 2021
Huntington Disease - Pipeline by Wave Life Sciences Ltd, 2021
Huntington Disease - Dormant Projects, 2021
Huntington Disease - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Huntington Disease, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Top 10 Molecule Types, 2021
Number of Products by Stage and Top 10 Molecule Types, 2021